Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years

• DOI: 10.1111/ggi.13919
• Publication Date: 2020-04-08T09:31:40Z
• Authors: Akiyoshi Kinoshita; Kazuhiko Koike; Yusuke Mizuno; Itsuro Ogata; Yutaro Kobayashi; Kiyoshi Hasegawa; Koichi Shiraishi; Hideo Yoshida; Ryo Nakata; Norie Yamada; Kiyomi Yasuda
• Keywords: Adult; Aged, 80 and over; Cyclopropanes; Male; 0301 basic medicine; Aminoisobutyric Acids; Pyrrolidines; Genotype; Proline; Lactams, Macrocyclic; Middle Aged; Antiviral Agents; Hepatitis C; 12. Responsible consumption; 3. Good health; 03 medical and health sciences; Japan; Leucine; Quinoxalines; Humans; Benzimidazoles; Drug Therapy, Combination; Female; Aged

Opportunities to treat older patients with hepatitis C virus infection have increased. We investigated the efficacy and safety of glecaprevir/pibrentasvir in HCV aged ≥75 years.We retrospectively evaluated 131 treated at nine institutions Japan. The were divided into two groups according their age: elderly group (n = 43, years) younger 88, <75 years). compared clinical characteristics, virologic response adverse events between groups. predictive factors for also assessed.The presence cirrhosis (27.9%), a history hepatocellular carcinoma (23.3%) comorbidities (88.4%) more frequently observed than group. Six (14.0%) 19 (21.6%) dropped out before sustained 12 assessment. In intention-to-treat population, 86.0% 78.4% achieved (P 0.30). modified all 12. A total 27.5% experienced events. most was pruritus, significantly associated female sex, hemodialysis serum albumin baseline <4.0 g/dL.Glecaprevir/pibrentasvir therapy effective well tolerated, even years. Geriatr Gerontol Int 2020; ••: ••-••.